Civica Rx, the nonprofit generic drug company formed last year by 5 health systems in order to combat drug shortages and high prices for generic drugs, added 12 additional health systems this week, bringing the total to 750 hospitals in the United States joining the venture so far.
Civica Rx, the nonprofit generic drug company formed last year by 5 health systems in order to combat drug shortages and high prices for generic drugs, added 12 additional health systems this week, bringing the total to 750 hospitals in the United States joining the venture so far.
“We are thrilled to welcome these highly-regarded health systems to Civica as founding members,” said Martin VanTrieste, Civica Rx’s chief executive officer, in a statement. “Drug shortages have become a national crisis where patient treatments and surgeries are canceled, delayed, or suboptimal. We thank these organizations for joining us to make essential generic medicines accessible and affordable in hospitals across the country.”
The aim of the initiative is to reduce costs and create a more predictable supply of many medicines.
The 12 systems joining as founding members are:
The latest members join the previously announced governing members, which include Catholic Health Initiatives, the Gary and Mary West Foundation, HCA Healthcare, Intermountain Healthcare, Laura & John Arnold Foundation, Mayo Clinic, the Peterson Center on Healthcare, Providence St. Joseph Health, SSM Health, and Trinity Health.
In 2019, Civica Rx hopes to bring over 14 hospital-administered generic drugs to hospitals and healthcare systems. Additional medications, as prioritized by the healthcare systems, will be the next phase of focus. The company is working toward becoming an FDA approved manufacturer and will either directly manufacture generic drugs or sub-contract manufacturing.
Hospitals have been struggling with drug shortages and the problem is getting worse, Martin Makary, MD, MPH, a surgical oncologist, said on a recent Managed Care Cast podcast.
Last year, the FDA decided to start extending the expiration dates of IV saline fluids in order to help hospitals cope with the shortages.
If Civica RX is successful, hospitals could see price reductions of 50%, The Chicago Tribune reported Friday. The new company will initially focus on selling to hospitals, but may eventually expand to offer products more broadly.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.